文献速递妇科

晚期卵巢癌患者初次肿瘤减灭术与新辅助化疗后的生活质量:随机SCORPION试验(NCT01461850)结果

Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
PubMed 文献 · BJOG · 2023-06-19

在单中心随机试验中,171例IIIC/IV期高肿瘤负荷上皮性卵巢癌患者随机接受初次肿瘤减灭术(PDS,84例)或新辅助化疗后间歇性肿瘤减灭术(NACT/IDS,87例)。12个月时QLQ-C30总体健康评分两组无临床或统计学显著差异(NACT/IDS组 vs PDS组,平均差4.7,95%CI -4.99至14.4,p=0.340);纵向分析显示PDS组总体健康评分低于NACT组(平均差6.27,95%CI 0.440-12.11,p=0.035),但无临床相关性。

要点

  • 12个月时QLQ-C30总体健康评分NACT/IDS组与PDS组无显著差异(平均差4.7,95%CI -4.99至14.4,p=0.340)。
  • 纵向分析PDS组总体健康评分低于NACT组(平均差6.27,95%CI 0.440-12.11,p=0.035),但无临床相关性。
  • 作者认为NACT/IDS可能是适合PDS患者的可行选择。

核心结论

  • 12个月时两种治疗方式的总体生活质量无差异,但NACT/IDS组在12个月期间报告了更好的总体健康评分;这些发现进一步证实NACT/IDS可能是适合PDS患者的可行选择。

研究设计与样本

  • 单中心随机试验,纳入IIIC/IV期高肿瘤负荷上皮性卵巢癌患者,1:1随机接受PDS(PDS组)或NACT后IDS(NACT/IDS组)。
  • 2011年10月至2016年5月共入组171例患者(PDS=84;NACT/IDS=87)。
  • 使用欧洲癌症研究与治疗组织核心生活质量问卷(QLQ-C30)和卵巢癌模块(OV28)评估生活质量;共同主要结局为12个月时QLQ-C30总体健康评分(横断面分析)和两组间QLQ-C30总体健康评分随时间变化的平均差异(纵向分析)。

主要发现

  • 12个月时任何QoL功能量表均无临床或统计学显著差异,包括QLQ-C30总体健康评分(NACT/IDS组 vs PDS组,平均差4.7,95%CI -4.99至14.4,p=0.340)。
  • 纵向分析显示PDS组总体健康评分低于NACT组(平均差6.27,95%CI 0.440-12.11,p=0.035),但无临床相关性。

临床怎么用

  • 作者认为NACT/IDS可能是适合PDS患者的可行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of treatment with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), versus primary debulking surgery (PDS), on quality of life (QoL) in patients with advanced epithelial ovarian cancer (EOC). DESIGN: Randomised trial conducted in a single institution. SETTING: Division of Gynaecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. SAMPLE: Patients with stage-IIIC/IV EOC and high tumour load. METHODS: Patients were randomised (1:1) to undergo either PDS (PDS group) or NACT followed by IDS (NACT/IDS group). MAIN OUTCOME MEASURES: Quality-of-life (QoL) data, assessed using the European Organization for Research and Treatment of Cancer core QoL questionnaire (QLQ-C30) and ovarian cancer module (OV28); co-primary outcomes were the QLQ-C30 global health score at 12 months (cross-sectional analysis) and the difference in mean QLQ-C30 global health score over time between treatment groups (longitudinal analysis). RESULTS: From October 2011 to May 2016, 171 patients were enrolled (PDS = 84; NACT/IDS = 87). We observed no clinical or statistically significant difference between treatment groups in any of the QoL functioning scales at 12 months, including QLQ-C30 global health score (NACT/IDS group vs PDS group, mean difference 4.7, 95% CI -4.99 to 14.4, p = 0.340). Over time, we found lower global health scores for those undergoing PDS than for those receiving NACT (difference in mean score 6.27, 95% CI 0.440-12.11, p = 0.035), albeit this was not clinically relevant. CONCLUSIONS: We found no difference in global QoL related to treatment approach at 12 months, even though patients in the NACT/IDS group reported better global health scores across the 12-month period compared with the PDS group; these findings further confirm that NACT/IDS might be a feasible option for patients unsuitable for PDS.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Marchetti C, Giannarelli D, Vizzielli G, et al. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850). BJOG. 2023. PMID: 37334772. doi:10.1111/1471-0528.17558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。